Travaux scientifiques

Doç. Dr. Hatice Bölek

74 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

    Medicina, 2026

    DOI 10.3390/medicina62050984 PMID 42195237 Texte intégral en libre accèsSource : OpenAlex

  2. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

    Cancers, 2026

    DOI 10.3390/cancers18132127 PMID 42449669 Texte intégral en libre accèsSource : OpenAlex

  3. Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16664-1 Texte intégral en libre accèsSource : OpenAlex

  4. Real-world treatment patterns and survival outcomes in HER2-positive metastatic gastric cancer

    Akademik Gastroenteroloji Dergisi, 2026

    DOI 10.17941/agd.1987603 Texte intégral en libre accèsSource : ORCID

  5. Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco-25-02722 PMID 41849717 Source : ORCID

  6. Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration-Sensitive Prostate Cancer

    The Prostate, 2026

    DOI 10.1002/pros.70062 PMID 40993982 2 citations (Europe PMC) Source : ORCID

  7. Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations

    The Oncologist, 2026

    DOI 10.1093/oncolo/oyag203 PMID 42159577 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  8. Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-35435-3 PMID 41548007 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  9. Prognostic Impact of Intraductal Carcinoma in Patients with Metastatic Prostate Cancer Treated with Abiraterone Acetate or Enzalutamide

    Bulletin of Urooncology, 2026

    DOI 10.4274/uob.galenos.2026.2025.12.1 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  10. Aspirin use and outcomes with immune checkpoint inhibitors in metastatic cancer.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e14584 1 citation (OpenAlex) Source : OpenAlex

  11. Survival Outcomes and Prognostic Factors in Head and Neck Adenoid Cystic Carcinoma Following Curative Surgery

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-11-9 Texte intégral en libre accèsSource : OpenAlex

  12. EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression

    Prostate Cancer and Prostatic Diseases, 2026

    DOI 10.1038/s41391-026-01124-5 PMID 42209844 Texte intégral en libre accèsSource : OpenAlex

  13. Prognostic Value of Baseline Cervical CT-derived Muscle Density as a Surrogate of Myosteatosis in Patients with Head and Neck Cancer

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-7-2 Texte intégral en libre accèsSource : OpenAlex

  14. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

    癌症：英文版, 2025

    DOI 10.1002/cac2.70003 PMID 39927571 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  15. The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf186 PMID 40577354 Texte intégral en libre accèsSource : OpenAlex

  16. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

    Immunotherapy, 2025

    DOI 10.1080/1750743x.2025.2527019 PMID 40611593 Texte intégral en libre accèsSource : OpenAlex

  17. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

    Cancers, 2025

    DOI 10.3390/cancers17172730 PMID 40940827 Texte intégral en libre accèsSource : ORCID

  18. FOLFIRINOX: The best adjuvant treatment for ampullary adenocarcinoma?

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16261 Source : ORCID

  19. Re: Hilin Yildirim, Katja K.H. Aben, Maarten J. Bijlsma, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol 2025;8:623–31

    European Urology Oncology, 2025

    DOI 10.1016/j.euo.2025.06.014 PMID 40784827 Source : ORCID

  20. Confirmation of Large Language Models in Head and Neck Cancer Staging

    Diagnostics, 2025

    DOI 10.3390/diagnostics15182375 PMID 41008746 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  21. A retrospective multicenter study on solitary fibrous tumors: investigation of clinical features and management approaches

    Journal of Health Sciences and Medicine, 2025

    DOI 10.32322/jhsm.1762045 Texte intégral en libre accèsSource : ORCID

  22. Re: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial

    ESMO Open, 2025

    DOI 10.1016/j.esmoop.2025.105765 PMID 40907205 Texte intégral en libre accèsSource : ORCID

  23. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14165868 PMID 40869694 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  24. Role of immune check point inhibitor rechallenge in metastatic renal cell carcinoma

    Kidney Cancer, 2025

    DOI 10.1177/24684562251357795 Texte intégral en libre accèsSource : ORCID

  25. Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS)

    European Journal of Cancer, 2025

    DOI 10.1016/j.ejca.2025.115226 PMID 39813762 3 citations (Europe PMC) Source : ORCID

  26. Impact of comorbidity on survival in cancer patients receiving immune checkpoint inhibitors

    Clinical and Translational Oncology, 2025

    DOI 10.1007/s12094-025-03848-7 PMID 39873944 4 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  27. Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf213 PMID 40694485 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  28. Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    Clinical and Translational Oncology, 2025

    DOI 10.1007/s12094-024-03813-w PMID 39812937 6 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  29. Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14654-3 PMID 40713516 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  30. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

    Therapeutic Advances in Medical Oncology, 2025

    DOI 10.1177/17588359251331540 PMID 40297625 Texte intégral en libre accèsSource : ORCID

  31. Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

    Cancer Immunology, Immunotherapy, 2025

    DOI 10.1007/s00262-025-04230-w PMID 41236632 10 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  32. Real-world treatment patterns and survival outcomes in metastatic head and neck adenoid cystic carcinoma

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14884-5 PMID 41029524 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  33. Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study

    JCO Global Oncology, 2025

    DOI 10.1200/go-25-00376 PMID 41160781 6 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  34. The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617

    The Prostate, 2025

    DOI 10.1002/pros.24804 PMID 39344207 4 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  35. The prognostic value of elimination rate constant K score of prostate-specific antigen in metastatic castration-resistant prostate cancer patients treated with docetaxel

    Prostate International, 2025

    DOI 10.1016/j.prnil.2024.11.007 PMID 40620874 2 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  36. Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study

    European Urology Focus, 2025

    DOI 10.1016/j.euf.2025.05.020 PMID 40738794 7 citations (OpenAlex) Source : OpenAlex

  37. Sequential use of targeted radioligand therapies in metastatic castration-resistant prostate cancer: A case report and systematic review

    Critical Reviews in Oncology/Hematology, 2025

    DOI 10.1016/j.critrevonc.2025.105088 PMID 41397584 3 citations (OpenAlex) Source : OpenAlex

  38. Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical Trials

    European Urology Oncology, 2025

    DOI 10.1016/j.euo.2025.05.003 PMID 40447512 3 citations (OpenAlex) Source : OpenAlex

  39. Immunotherapy rechallenge in metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf426 PMID 41452751 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  40. Menopausal Status at Diagnosis is a Prognostic Indicator in Patients who are Operated for Uterine Carcinosarcoma

    Journal of Ankara University Faculty of Medicine, 2025

    DOI 10.4274/atfm.galenos.2025.79058 Texte intégral en libre accèsSource : OpenAlex

  41. Enhancing outcomes in mCRPC: The impact of androgen receptor inhibitor sequencing before ¹⁷⁷Lu-PSMA-617 therapy.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e17068 Texte intégral en libre accèsSource : OpenAlex

  42. Comparison of frontline FOLFIRINOX with fluorouracil-based and gemcitabine-basedchemotherapies in metastatic ampullary adenocarcinoma: A multicenter cohort study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16264 Texte intégral en libre accèsSource : OpenAlex

  43. 2681eP Real-world comparison of immunotherapy (IO)-based combinations in intermediate/poor-(int/poor-) risk patients (pts) with non-clear cell Renal Cell Carcinoma (nccRCC): The ARON-1 multicenter experience

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3292 Texte intégral en libre accèsSource : OpenAlex

  44. 3060eP Immunomodulatory effect of cisplatin versus carboplatin on tumor microenvironment and anti-PD-1 response: A multicenter real-world analysis

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3673 Texte intégral en libre accèsSource : OpenAlex

  45. Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer

    Cancer Investigation, 2025

    DOI 10.1080/07357907.2025.2598042 PMID 41451788 Source : OpenAlex

  46. Outcomes and prognostic markers in locally advanced head and neck squamous cell carcinoma underwent chemoradiotherapy

    Discover Oncology, 2025

    DOI 10.1007/s12672-025-04350-w PMID 41456218 Texte intégral en libre accèsSource : OpenAlex

  47. Rezeksiyon Edilmiş Uterin Karsinosarkom Tanılı Hastalarda Prognostik Bir Gösterge Olarak Tanı Anındaki Menopozal Durum

    DergiPark (Istanbul University), 2025

    Source : OpenAlex

  48. Soliter fibröz tümörler üzerine retrospektif çok merkezli bir çalışma: klinik özellikler ve tedavi yaklaşımlarının incelenmesi

    DergiPark (Istanbul University), 2025

    Source : OpenAlex

  49. Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102282 PMID 39709686 2 citations (Europe PMC) Source : OpenAlex

  50. Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer

    JCO Global Oncology, 2024

    DOI 10.1200/go.24.00201 PMID 39208383 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex